16 results about "Aqueous flow" patented technology

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and / or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry / exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and / or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry / exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

An aqueous drag reducer having the components of water, a hydrocarbon soluble rheology modifier and an ultra-high molecular weight polymer. This aqueous drag reducer is also soluble in hydrocarbons.

Disclosed herein is a device, system and method configured to safely regulate aqueous outflow in a patient's eye while dynamically maintaining a normal range of intraocular pressure. An example thin-film implant comprises a plurality of topographical features implemented on first and second surfaces of the implant. The topographical features include a network of interconnected channels configured to direct aqueous humor in a patient's eye to flow through and across the surfaces of the thin-film implant for lowering intraocular pressure. Multiple control structures are implemented on one or more selected locations of the first and second surfaces to regulate the aqueous humor in the patient's eye.

The invention provides an aqueous liquid composition for ophthalmic administration, comprising therapeutically effective amounts of a ketorolac compound and of a corticosteroid, wherein the ketorolac compound is present in an essentially dissolved form; wherein the corticosteroid is present in the form of suspended particles; and wherein the composition exhibits an acidic pH of about 6.5 or less. The invention further provides compositions as disclosed herein for use in the prevention or treatment of ocular inflammation and methods for preventing or treating ocular inflammation in a subject.

Disclosed herein are ophthalmic compositions, such as non-aqueous liquid ophthalmic compositions, comprising lifitegrast and at least one semifluorinated alkane, such as 1-perfluorohexyloctane (F6H8); and methods of treating or preventing at least one ocular condition, such as dry eye disease, with such compositions. The ophthalmic compositions can be further provided in a container closure system, such as a polypropylene (PP) bottle or in a kit.

The present invention relates to a device for removing gases from aqueous liquids, in particular blood, comprising: a first compartment which is permeated by the aqueous liquid during operation of the device; a second compartment which is permeated by a purge gas during operation of the device, the first compartment and the second compartment being separated from each other by a semipermeable membrane; and a third compartment which is permeated by a liquid proton donor during operation of the device, the liquid proton donor being an organic or inorganic acid, the first compartment and the third compartment being separated from each other by an ion-permeable membrane, and the ion-permeable membrane comprising at least one cationic conductor.

An ophthalmically-acceptable aqueous liquid composition is provided comprising an amine buffer and a muscarinic acetylcholine receptor antagonist which comprises a hydrolysable bond wherein the muscar

A method of treating human or animal tissue, the method comprising the step of: i. directing a stream of an aqueous liquid comprising gas bubbles excited by acoustic energy towards a wound or anatomical pocket in human or animal tissue, or towards an anatomical space or potential space in human or animal tissue, or towards soft or hard tissue in an oral cavity or elsewhere in the human or animal body, or towards tissue in a nasal cavity, or towards tissue associated with sinuses, eye, ear, digestive and genito-urinary systems, thereby to treat the human or animal tissue with the stream. The output stream can clean a wound in human or animal tissue, and can treat the wound by healing the wound, for example by stimulating fibroblasts in the wound tissue and causing, promoting or enhancing re-epithelialisation of epidermal tissue in the wound.

An oral care composition comprising a persulfate whitening agent, a non-aqueous dispersant having a non-aqueous liquid, and a structure builder.

Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

An apparatus (100) for preparing a mixture of a nutritional concentrate and an aqueous liquid in a capsule (200) comprises a capsule holder (101) configured to receive the capsule (200), the capsule (200) comprising a chamber (202), a membrane (202) sealing the chamber (202), and an agitator (203). The device (100) comprises an injection needle (1) configured to pierce the membrane (202) and inject an aqueous liquid into the chamber (201) of the capsule (200) and a venting needle (2) configured to further pierce the membrane (202) and inject a liquid into the chamber (201) of the capsule (200). Furthermore, the apparatus (100) comprises a driver (3) configured to engage with the stirrer (203) to mix the liquid with the nutritional concentrate in the chamber (201) in the mixing cycle and a control unit (4) configured to control the liquid supply (31) and the driver (3).

Disclosed herein is a device, system and method configured to safely regulate aqueous outflow in a patient's eye while dynamically maintaining a normal range of intraocular pressure. An example thin-film implant comprises a plurality of topographical features implemented on first and second surfaces of the implant. The topographical features include a network of interconnected channels configured to direct aqueous humor in a patient's eye to flow through and across the surfaces of the thin-film implant for lowering intraocular pressure. Multiple control structures are implemented on one or more selected locations of the first and second surfaces to regulate the aqueous humor in the patient's eye.

The present invention provides ophthalmic acceptable formulations of atropine and other muscarinic acetylcholine receptor antagonists, which can be heat sterilized without significant degradation of the muscarinic acetylcholine receptor antagonists. The formulations are less acidic than previous muscarinic acetylcholine receptor antagonist ocular formulations, making them more comfortable when administered to the eye.